Skip to main content

Table 3 CERTAIN patients not included in the primary analysis population because they had not previously received anti-TNF therapy at the time of initiation of a new biologic

From: Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients

 

All

Anti-TNF agents initiators

Non-anti-TNF agents initiators

Standardized absolute mean difference

Total, n

913

762

151

 

Age (median, IQR), years

56 [48,65]

55 [47,64]

60 [51,69]

0.349

Female, n (%)

675 (77.2)

563 (76.9)

112 (78.9)

0.047

Caucasian, n (%)

708 (80.8)

596 (81.2)

112 (78.9)

0.058

RA disease duration (median, IQR), years

2 [1,7]

2 [1,6]

4 [1,11]

0.294

CDAI (median, IQR)

27 [20,37]

26 [20,36]

28 [20,38]

0.115

DAS28-CRP (median, IQR)

4.8 [4.1,5.5]

4.9 [4.1,5.5]

4.6 [3.9,5.4]

0.114

Biologic Monotherapy, n (%)

221 (24.2)

178 (23.4)

43 (28.5)

0.117

Concurrent DMARDs, n (%)

692 (75.8)

584 (76.6)

108 (71.5)

0.117

  MTX only, n (%)

486 (53.2)

425 (55.8)

61 (40.4)

0.311

  MTX dose (med, IQR) mg/week

20 [15,20]

20 [15,20]

20 [15,20]

0.149

  MTX plus other DMARDs, n (%)

95 (10.4)

81 (10.6)

14 (9.3)

0.045

  Leflunomide only, n (%)

39 (4.3)

29 (3.8)

10 (6.6)

0.127

  Sulfasalazine only, n (%)

13 (1.4)

10 (1.3)

3 (2)

0.053

  Hydroxychloroquine only, n (%)

33 (3.6)

27 (3.5)

6 (4)

0.023

Concomitant prednisone, n (%)

287 (31.4)

243 (31.9)

44 (29.1)

0.060

  Prednisone dose (median, IQR) mg

5 [5,10]

5 [5,10]

5 [5,6]

0.256

  No use, n (%)

636 (69.7)

528 (69.3)

108 (71.5)

0.049

  Prednisone <5 mg, n (%)

37 (4.1)

27 (3.5)

10 (6.6)

0.140

  Prednisone 5- <10 mg, n (%)

134 (14.7)

111 (14.6)

23 (15.2)

0.019

  Prednisone ≥ 10 mg, n (%)

106 (11.6)

96 (12.6)

10 (6.6)

0.203

Number of prior biologics exposed to (median, IQR)

0 [0,0]

0 [0,0]

0 [0,0]

0.425

Number of prior non-biologic DMARDs exposed to (median, IQR)

1 [1,2]

1 [1,2]

2 [1,2]

0.343

Biologic started at enrollment, n (%)

    

  Adalimumab

268 (29.4)

268 (35.2)

N/A

N/A

  Infliximab

180 (19.7)

180 (23.6)

N/A

N/A

  Etanercept

205 (22.5)

205 (26.9)

N/A

N/A

  Golimumab

20 (2.2)

20 (2.6)

N/A

N/A

  Certolizumab pegol

89 (9.7)

89 (11.7)

N/A

N/A

  Rituximab

15 (1.6)

N/A

15 (9.9)

N/A

  Abatacept

100 (11)

N/A

100 (66.2)

N/A

  Tocilizumab

36 (3.9)

N/A

36 (23.8)

N/A

Co-morbidities, n (%)

    

  History of Cardiovascular disease*

71 (7.8)

54 (7.1)

17 (11.3)

0.145

  History of Hypertension

203 (28.2)

165 (26.9)

38 (35.8)

0.194

  History of Diabetes Mellitus

63 (9)

52 (8.7)

11 (11.2)

0.085

  Hyperlipidemia (Defined as: Total cholesterol > 240 mg/dL at baseline visit)

111 (13.5)

92 (13.3)

19 (14.2)

0.025

  History of Malignancy (includes non -melanoma skin cancers)

54 (5.9)

45 (5.9)

9 (6)

0.002

  1. Abbreviations: IQR interquartile range, CDAI clinical disease activity index, DAS28_CRP disease activity score with 28 joint counts and CRP (C- reactive protein) as the inflammatory marker.
  2. *History of cardiovascular disease included: cardiac revascularization procedures, ventricular arrhythmias, cardiac arrests, myocardial infarctions, acute coronary syndromes, unstable angina, coronary artery disease, congestive heart failure, stroke, transient ischemic attacks.
  3. (Data for patients enrolled as of October 7th 2013).